Friday, January 15, 2021

Fw: (LML) WHO will formally launch its new road map for NTDs on 28 January 2021

 


Leprosy Mailing List – January 15,  2021

 

Ref.:  (LML) WHO will formally launch its new road map for NTDs on 28 January 2021

 

From:  Henk Eggens, Santa Comba Dão, Portugal

 _____________________________________________________________________________________


Dear Pieter,

 

WHO, 11 January 2021, Neglected tropical diseases:


WHO to formally launch new road map for neglected tropical diseases for the next decade ( https://www.who.int/news/item/11-01-2021-neglected-tropical-diseases-who-to-formally-launch-new-road-map-for-next-decade )  on 28 January 2021.


Registration for the Zoom webinar (  https://who.zoom.us/webinar/register/WN_0-XfZsDjQTSpBsVaTIAS0Q ) is open for the virtual launch which comprises a 2-hour programme with the participation of Heads of State, Ministers of Health of several countries, WHO Director-General and Regional Directors and partner organizations.

The launch virtual campaign will start on 18 January with curated themes, roadmap-specific shareable content to amplify messages. These include video clips on various shifts of the new road map, the 2030 targets and potential challenges.

 

Relevant links:


1. Global consultation of National Leprosy Programme managers, partners and affected persons on Global Leprosy Strategy 2021–2030
Report of the virtual meeting 26–30 October 2020 https://www.who.int/publications/i/item/9789290228226

2. Global Leprosy Strategy 2021–2030; Overview by Erwin Cooreman MD MSc DTM&H, Team Leader, Global Leprosy Programme WHO
  https://www.who.int/docs/default-source/ntds/leprosy/global-consultation-on-global-leprosy-strategy-2021-2030/06-global-leprosy-strategy-overview.pdf

 

---
Henk Eggens

(henk.eggens@gmail.com)

____________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/3e2ea24e-dd57-426c-9084-a130708f0aafn%40googlegroups.com.

Tuesday, January 12, 2021

Fw: (LML) Dr Elisabeth Duncan


 

Leprosy Mailing List – January 12,  2021

 

Ref.:  (LML) Dr Elisabeth Duncan

 

From:  Sunil Deepak, Schio, Italy

____________________________________________________________________________________

 

Dear Pieter,

 

The second edition of the Textbook of Leprosy published by Springer is being prepared.

 

I am writing to you to ask for the LML readers in getting some information about Dr Elisabeth Duncan who used to be at ALERT and had written one of the chapters in the first edition of this book.

 

If anyone knows about her or can help in contacting her please do write to me.

 

Thanks in advance,

 

Dr Sunil Deepak

Schio (VI), Italy

Email: sunil.deepak@gmail.com

______________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/cce85e2b-e9a8-4d36-be8c-5d314b997296n%40googlegroups.com.

Thursday, January 7, 2021

Fw: (LML) MDT duration and ENL neuritis risk


 


Leprosy Mailing List – January 7,  2020

 

Ref.:  (LML) MDT duration and ENL neuritis risk

 

 

From:  Joel Almeida, London and Mumbai

 

 

Dear Pieter,

 

Front-line clues allow rapid improvements in the quality and efficacy of interventions. At the start of a new decade, we can focus on what demonstrably works and discard what does not. This reduces suffering for our patients and our people.  

 

Happy New Year to all,

 

Joel Almeida

= = = = =

 

 

MDT duration and ENL neuritis risk

 

Introduction

 

ENL (Erythema Nodosum Leprosum) is an extremely painful and distressing "reaction" condition often involving many organ systems. It occurs most commonly in highly bacillated types of HD (leprosy). 

 

Does the duration of MDT (multi-drug therapy) affect the risk of ENL neuritis among LL (lepromatous) patients? More specifically, does withdrawing MDT after 12 months have any impact on the risk of ENL neuritis subsequently? 

 

Methods

 

Comparison was made by Balagon, Gelber et al between one-year MDT and two-year MDT.(1) 58 LL patients given one-year MDT were compared to 139 LL patients given two-year MDT. 

 

Months 13 to 24 after the start of MDT are of particular interest. The one-year MDT group had no MDT during months 13 to 24, but the two-year MDT group did. 

 

Patients with signs of reaction were examined weekly or fortnightly.  ENL reactions were considered severe if there were  more than 20 ENL skin lesions or if papulonodules of ENL were associated with either severe joint pains, edema, high fever, other constitutional signs and symptoms of iritis, laryngitis, orchitis, and other organ involvement. Any neuritis was noted. Neuritis was defined as pain associated with swelling and tenderness of a nerve.

 

The incidence rate of ENL reactions with neuritis in the one-year MDT group during months 13 to 24 after the start of MDT can be compared to that in the two-year MDT group. The Incidence Rate Ratio is used.

 

Results

 

The results are shown in the Figure.

 

 

 

The Figure. (see attached file) The one-year MDT group showed a 600% increase in the risk of ENL with neuritis compared to the two-year MDT group, during months 13 to 24 after the start of MDT.

 

Discussion

 

It would be good to continue MDT beyond 12 months in LL patients. Otherwise they are needlessly subjected to a greatly multiplied risk of the painful, swollen and tender nerves found in the neuritis of ENL "reactions". 

 

Reference

 

1.    Balagon MVF, Gelber RH, Abalos RM, Cellona RV. Reactions following completion of 1 and 2 year multidrug therapy (MDT) Am J Trop Med Hyg  2010 Sep;83(3):637-44. doi: 10.4269/ajtmh.2010.09-0586

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/c9e30ac9-8c91-4cfb-a8dc-681b277870fen%40googlegroups.com.

Virus-free. www.avast.com

Wednesday, January 6, 2021

Fw: (LML) New publications on leprosy. January 2021

 

 
Leprosy Mailing List – January 5,  2021

 

Ref.:  (LML) New publications on leprosy. January 2021

 

From:  Annemiek Akerboom, Amsterdam, the Netherlands

 __________________________________________________________________________________

 


  Dear colleagues,


Infolep wishes you a healthy, joyful and prosperous new year!



Many of us look back at a challenging year. A year in which we faced uncertainty, fear, restrictions and losses. But 2020 has also shown us that we are resilient, innovative and cooperative. A lot of research has been conducted on leprosy and COVID-19 and beautiful initiatives emerged to support each other and especially marginalized populations. A crisis like the COVID-19 pandemic disproportionally affects marginalized individuals, such as people affected by leprosy, and more clearly exposed the impact of stigma. We truly hope 2021 will be the year in which we will build back better.

This new year kick-starts with an exciting month, as we will celebrate World Leprosy Day on 30 January and the WHO will launch the NTD Roadmap on 28 January.

Below you will find the list with new publications on leprosy and interesting events. Feel free to contact me to receive full-text versions if these cannot be found through the Infolep portal. Also, I would be happy to assist you with literature searches.


Thank you for your interest and support in 2020. We look forward to best serve your information needs and collectively work towards a world without leprosy in the coming years.

Warm regards,

Anniek Akerboom

Infolep Coordinator
www.leprosy-information.org
a.akerboom@infolep.org



 

 


Highlighted

 



World Leprosy Day
31 Jan 2021
Learn more


Interim Advice on the use of Rifampicin for post-exposure prophylaxis (PEP), in light of recent information on nitrosamine impurities in rifampicin
ILEP Technical Commission. 2020;
Learn more


Thirteenth meeting of the Strategic and Technical Advisory Group for Neglected Tropical Diseases, 15–17 September 2020
World Health Organization. 2020;
Learn more

 


Leprosy & COVID-19

 



 



Severe Type 2 leprosy reaction with COVID-19 with a favourable outcome despite continued use of corticosteroids and methotrexate and a hypothesis on the possible immunological consequences.
Saxena S, Khurana A, B S, et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020; 
Learn more

 



 



New publications

 



 



The adverse drug effects of dapsone therapy in leprosy: a systematic review
Hilder R, Lockwood D. Leprosy review. Lepra. 2020; 91 (3) : 232-243. 
Learn more

Hansen's Disease: differences in clinical presentation among Latin American and South East Asian born patients identified in Los Angeles County, California (1995–2016)
Croker C, Phommasith J, Jerskey R, et al. Leprosy review. Lepra. 2020; 91 (3) : 244-254. 
Learn more

Leprosy in a prison population: A new active search strategy and a prospective clinical analysis.
Filho F, Santana J, de Almeida R, et al. PLoS neglected tropical diseases. 2020; 14 (12) : e0008917. 
Learn more

Assessing the prospect of a common health-related stigma reduction response: Cross-perspectives of people living with stigmatised health conditions in Indonesia.
Rai S, Syurina E, Peters R, et al. Global public health. 2020; 
Learn more

Leprosy post-exposure prophylaxis: innovation and precision public health.
Moraes M, Düppre N. The Lancet. Global health. 2021; 9 (1) : e8-e9. 
Learn more

Why can't we control Morbus Hansen?
Naafs B. info Hansen. 2020; 
Learn more

Polymorphisms in mitochondrial ribosomal protein S5 (MRPS5) are associated with leprosy risk in Chinese.
Xing Y, He J, Wen Y, et al. PLoS neglected tropical diseases. 2020; 14 (12) : e0008883. 
Learn more

Single-Nucleotide Polymorphisms in Genes Predisposing to Leprosy in Leprosy Household Contacts in Zhejiang Province, China
Shen Y, Long S, Kong W, et al. Pharmacogenomics and Personalized Medicine. Informa UK Limited. 2020; 
Learn more

Analysis of the Myeloid-Derived Suppressor Cells and Annexin A1 in Multibacillary Leprosy and Reactional Episodes
Damazo AS, Silva SFD, Cavalcante LRDS, et al. Research Square. 2020; 
Learn more

Misdiagnosis of leprosy in Brazil in the period 2003 - 2017: spatial pattern and associated factors.
Neves K, Nobre M, Machado L, et al. Acta tropica. 2020; 
Learn more

The Dermlep Study Part 2: Results of a Nation-Wide Survey of Dermatologists' Access to Quality Leprosy Services at their Clinics and Hospitals in India.
Rao NP, Rathod S, Suneetha S, et al. Indian dermatology online journal. 2020; 11 (6) : 895-903. 
Learn more

Gandhi's Evolving Discourse on Leprosy
Kakar S. Palgrave Studies in the History of the Media. Springer International Publishing. 2020;
Learn more

Relationship between Plantar Pressure and Sensory Disturbance in Patients with Hansen's Disease-Preliminary Research and Review of the Literature.
Tashiro S, Gotou N, Oku Y, et al. Sensors (Basel, Switzerland). 2020; 
Learn more

Synthetic Phenolic Glycolipids for application in diagnostic tests for leprosy.
van Dijk HJ, van Hooij A, Groot ML, et al. Chembiochem : a European journal of chemical biology. 2020;
Learn more

Functional biomarker signatures of circulating T-cells and its association with distinct clinical status of leprosy patients and their respective household contacts.
Marçal P, Gama R, de Oliveira L, et al. Infectious diseases of poverty. 2020; 9 (1) : 167. 
Learn more

Why do Leprosy patients default treatment; Evidence from Sri Lanka
Arnold M. International Journal of Progressive Sciences and Technologies. 2020; 23 (2) : 654-659. 
Learn more

HARP: a database of structural impacts of systematic missense mutations in drug targets of Mycobacterium leprae.
Vedithi S, Malhotra S, Skwark M, et al. Computational and structural biotechnology journal. 2020; 
Learn more

Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Cruz R, Bührer-Sékula S, Penna G, et al. Anais brasileiros de dermatologia. 2018; 93 (3) : 377-384.
Learn more

Effectiveness of the retreatment of patients with multibacillary leprosy and episodes of erythema nodosum leprosum and/or persistent neuritis: a single-center experience.
Lastória J, Putinatti M, de Almeida T, et al. Anais brasileiros de dermatologia. 2018; 93 (2) : 181-184. 
Learn more

Endocrinological Testicular Dysfunction in Patients with Lepromatous Leprosy and the Impact of Disease on Patient's Quality of Life.
Mohta A, Agrawal A, Sharma P, et al. Indian dermatology online journal. 2020; 11 (6) : 959-964. 
Learn more

Hanseniasis in the municipality of Western Amazon (Acre, Brazil): are we far from the goal of the World Health Organization?: Hansen and Western Amazon.
Araújo F, Abreu L, Laporta G, et al. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2020; 
Learn more

Epidemiological profile and tendency of leprosy in people younger than 15 years.
Santos Á, Costa A, de Souza J, et al. Revista da Escola de Enfermagem da U S P. 2020; 
Learn more

Risk Factors Related to the Events of Leprosy in Children age 5-14 Years in City of Sorong West Papua
Maryen Y, Parlaungan J, Samaran E, et al. Medico Legal Update. 2020; 20 (4) : 2160-2167. 
Learn more

Spectrum of Inborn errors of immunity in a cohort of 90 patients presenting with complications to BCG vaccination in India.
Yadav R, Dalvi A, Gupta M, et al. Scandinavian journal of immunology. 2020;
Learn more

Empowerment Based on Collaborative Governance in Leprosy Patients In Central Java
Imam Al Hafis R, Larasati E, Warsono H, et al. 6th International Conference on Social and Political Sciences (ICOSAPS 2020). 2020; 
Learn more

La influencia del poder colonial sobre la población y la naturaleza determinaron los asentamientos de la enfermedad de Hansen en Surinam.
Menke H, Pieters T, Menke J. Revista de Leprología. 2020; 32 (6) : 411-439. 
Learn more

Porcentajes variables de casos de lepra paucibacilar en la notificación global de casos de lepra.
Butlin R, Lockwood DNJ. Revista de Leprología. 2020; 32 (6) : 441-449. 
Learn more

 



 



Interesting events

 



 



ISNTD Connect Webinar: Disease management, disability and inclusion: disability inclusion to achieve the NTD Roadmap targets
03 Dec 2020 | Recording
Watch it here

ISNTD Connect Webinar: Health Technologies for NTDs: Accelerating Research & Development for Impact
17 Dec 2020 | Recording
Watch it here

Sasakawa Health Foundation's Webinar Series 'Issues in Leprosy amid the Coronavirus Pandemic':

WHO NTD Roadmap launch
28 Jan 2021 | Online
The link to register will be provided soon

World NTD Day
30 Jan 2021

World Leprosy Day in India
30 Jan 2021

World Leprosy Day
31 Jan 2021

 



 



 



 



Websites & Services

 



 




Info Hansen - A innovative hub for knowledge sharing about Hansen's Disease
https://www.infohansen.org/

ALLF - Official website of the Association des Léprologues de Langue Française
https://allf.medicalistes.fr/

LML - Leprosy Mailing List - a free moderated email list that allows all persons interested in this theme to share ideas, information, experiences, and questions.
https://groups.google.com/forum/#!forum/leprosymailinglist

InfoNTD - Information on cross-cutting issues in Neglected Tropical Diseases (NTDs)
https://www.infontd.org/




 

 



 



Newsletters & Journals

 



 



ILEP newsletter archive: ilepfederation.org/news-events/#archive
 
GPZL newsletter archive: zeroleprosy.org/newsletter-archive

Hansenologia Internationalis: www.ilsl.br/revista/atual.php

Indian Journal of Leprosy: www.ijl.org.in/index.html

Leprosy Review: leprosyreview.org
Leprosy Review Repository (1928-2001): leprev.ilsl.br/arquivo.php

Fontilles Revista de Leprología: www.leprosy-information.org/resource/revista-de-leprologia

 



 



GDPR & the Infolep newsletter

 



 




New EU data protection regulations came into force on 25 May 2018. We have been reviewing our practices with regard to the GDPR, including our privacy statement and mailing list. Infolep sends out monthly e-mails to its subscribers with an overview of recent publications on leprosy. The purpose of this activity is to keep subscribers up to date. Infolep will only process the data we have (names, email addresses) for the purpose of sending you the newsletter. We take your security seriously and will never share your contact details with anyone else. We hope the content from the Infolep newsletter is useful to you, but you can update your preferences or unsubscribe from this list at any time.



 

 



 


 






Copyright © 2020 Infolep, All rights reserved.
You are receiving this mail because you opted in at our website

Our mailing address is:
Infolep
Wibautstraat 137-k
Amsterdam, 1097 DN
Netherlands

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

______________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/5d948d4a-c5d0-4e77-875d-3a5b4d7615f6n%40googlegroups.com.

Thursday, December 31, 2020

Fw: (LML) The Brazilian Public Health System (SUS) will offer clarithromycin for the treatment of resistant leprosy



Leprosy Mailing List – December 31,  2020

 

Ref.:  (LML) The Brazilian Public Health System (SUS) will offer clarithromycin for the treatment of resistant leprosy

From:  Rodrigo Sena, Brasília, Brazil

_____________________________________________________________________________________________________________________________________________


Dear Pieter,

I am writing to disclose that Brazil will adopt clarithromycin for the treatment of drug-resistant leprosy.

I made a brief summary of the scientific and economic evidence studies, which supported the decision of the public health system in Brazil (SUS).
(attached file).

We are honored to contribute.



Greetings
,


Rodrigo Sena

 

National Leprosy Program of Brazil.

_________________________________________________________________________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/eee9c8fa-76ae-40f3-9c60-4ee379d057dfn%40googlegroups.com.

Fw: (LML) Previously treated but neglected persons multiply the risk of HD in a household




From: leprosymailinglist@googlegroups.com <leprosymailinglist@googlegroups.com> on behalf of Pieter Schreuder <editorlml@gmail.com>
Sent: 31 December 2020 18:04
To: Leprosy Mailing List <leprosymailinglist@googlegroups.com>
Subject: (LML) Previously treated but neglected persons multiply the risk of HD in a household
 

 

Leprosy Mailing List – December 31,  2020

 

Ref.:  (LML) Previously treated but neglected persons multiply the risk of HD in a household

 

From:  Joel Almeida, London and Mumbai

______________________________________________________________________________________

 

Dear Pieter and colleagues,

 

Meticulous observational and analytical studies at the frontlines can unearth important clues. Unexpected clues tend to be the most valuable, because they can make the difference between harm and benefit. 

 

Joel Almeida

 

= = = = =

 

Previously treated but neglected persons multiply the risk of HD in a household

 

Methods

 

The methods used were described by Vijayakumaran et al.(1) In summary, during the 11 years ending December 1994, all consecutively diagnosed skin-smear positive and previously untreated "index" patients living in a defined geographical area were started on 24 months of MDT. Every household contact of every such "index" patient was physically examined for HD. The physical examinations were repeated at annual intervals. New arrivals into each such household, who joined after the start of MDT in the "index" patient, likewise were examined. These new arrivals will be referred to below as "newcomers". Further, the presence or absence of "co-prevalent" persons was noted. These "co-prevalent" persons consisted of those previously started on anti-microbial treatment, including those who had already completed treatment prior to enrollment of the "index" patient.

The incidence rate of all types of HD in this defined area with a well-established control programme, estimated from sample surveys, was about 900 new patients/million population/year.

 

Results among "newcomer" children

 

The incidence rate of HD among "newcomer" children is shown in Figure 1.

 

Figure 1.  (see attached file) Presence of a previously treated patient multiplied the risk of HD among "newcomer" children in a household, despite prior start of treatment in a newly diagnosed "index" patient.(1) Excess risk to "newcomer" children in household endured for as long as observation continued - up to 9 years

 

The presence of a previously treated patient in the household apparently increased the risk of HD among "newcomer" children to over 25 times that in the general population of the area, during the initial three years after the start of MDT in the "index" patient. When a previously treated patient was present in the household, treatment of the index patient alone did not suffice to reduce the risk to the "background" population level. Even seven to nine years after the start of 24 month MDT in the "index" patient, "newcomer" children showed a greatly elevated risk of HD if a previously treated (but since neglected) patient was present in the same household. 

 

Discussion

 

Prolonged anti-microbial protection of previously treated but genomically anergic (2-5) persons  in endemic areas is likely to reduce dramatically the risk of HD in their household contacts. It also would help protect the individuals from reactions,(6-9) which can be painful, distressing, and aggravate nerve damage. Reinfection in previously treated anergic patients remains a sustained threat in endemic areas.(10)

 

Preventive antimicrobials among contacts of such neglected previously treated but anergic patients would need to continue for over nine years, to cope with the sustained duration of risk. It seems wiser to rely on prolonged anti-microbial protection of the anergic patients.

 

Prolonged anti-microbial protection of patients with possible anergy (eg., LL patients) can be achieved by

a) prolonged MDT, after the usual duration. At least until smear negativity.

 

or

 

b) prolonged anti-microbials after the usual duration of MDT, with a combination of 3 bactericidal drugs. Some enlightened private practitioners and centres of excellence in endemic areas of India and Brazil already protect LL patients with combinations of bactericidal drugs after MDT. 

 

This HD control area, served by the Schieffelin Centre in Karigiri (India) had earlier produced one of the world's great successes in rapidly reducing the incidence rate of LL HD (16%/year). As long as prolonged anti-microbial protection was ensured for persons with anergy, the exemplary success continued (as discussed here previously). Resurgence in LL HD occurred only after fixed-duration MDT replaced prolonged anti-microbial protection in even LL patients. Since the introduction of fixed duration MDT (in place of MDT till smear negativity) the world too has experienced stagnation in the number of new MB HD patients per year. This is evidenced in Weekly Epidemiological Records. MB types of HD rarely self-heal. Therefore sooner or later they come to the attention of health services and form a more reliable epidemiological indicator than most other indicators.

As the best young local talent is invited and encouraged to participate in HD work, we can expect increasingly astute investigations and openness to front-line clues. The evidence so far indicates that, in endemic areas, it is neither safe nor fair to exclude persons with anergy (mostly LL) from prolonged anti-microbial protection.

 

References

 

1.     Vijayakumaran P, Jesudasan K, Mozhi NM, Samuel JD. Does MDT arrest transmission of leprosy to household contacts? Int J Lep 1998; Jun;66(2):125-30.

 

2.     Chakravarti MR, Vogel F. A twin study on leprosy Georg Thieme Publishers, Stuttgart, Germany; 1973

 

3.      Sartori PVU, Penna GO, Bührer-Sékula S et al. Human Genetic Susceptibility of Leprosy Recurrence. Scientific Reports 2020 volume 10, Article number: 1284

 

4.      Gaschignard J, Grant AV, Thuc NV et al. Pauci- and Multibacillary Leprosy: Two Distinct, Genetically Neglected Diseases. PLoS Negl Trop Dis. 2016 May 24;10(5):e0004345. doi: 10.1371/journal.pntd.0004345


5.      Wang N, Wang Z, Wang C et al. Prediction of leprosy in the Chinese population based on a weighted genetic risk score. PLoS Negl Trop Dis. 2018 Sep 19;12(9):e0006789. doi: 10.1371/journal.pntd.0006789.

 

6.      Save MP, Dighe AR, Natrajan M & Shetty VP. Association of viable Mycobacterium leprae with Type 1 reaction in leprosy. Lepr Rev (2016) 87, 78–92


7.      Arora P, Sardana K, Agarwal A, Lavania M. Resistance as a cause for chronic steroid dependent ENL - a novel paradigm with potential implications in management. Lepr Rev (2019) 90, 201– 205

8.      Brito MDE F, Ximenes RA, Gallo ME, BÜhrer-SÉkula S. Association between leprosy reactions after treatment and bacterial load evaluated using anti PGL-I serology and bacilloscopy. Rev Soc Bras Med Trop. 2008;41 Suppl 2:67-72.

 

9.      FajardoT1, Villahermosa L, Eleanor F et al Comparative Clinical Trial in Multibacillary Leprosy with Long-Term Relapse Rates of Four Different Multidrug Regimens. Am. J. Trop. Med. Hyg., 2010, 83(3),  pp. 637–644

 

10.      Balagon MF, Cellona RV, dela Cruz E et al. Long-Term Relapse Risk of Multibacillary Leprosy after Completion of 2 Years of Multiple Drug Therapy (WHO-MDT) in Cebu, Philippines. American Journal of Tropical Medicine and Hygiene, 2009; 81, 5: 895-9. reviewed and analysed further in 19a. Almeida J Recurrence rate among MB patients following RFT. LML 2 June 2019.

______________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/69755738-33e0-428b-a67a-fab7a471e24bn%40googlegroups.com.

Wednesday, December 23, 2020

Fw: (LML) Factsheet Second Term Leprosy mandate


 

 

Leprosy Mailing List – December 23,  2020

 

Ref.:  (LML) Factsheet Second Term Leprosy mandate

 

From:  Alice Cruz, Quito, Ecuador

______________________________________________________________________________________

 

Dear friends and partners,


As I enter my second term as Special Rapporteur, I would like to thank all and each one of you for the precious support given to my mandate during its first term. With an added weight of responsibility and sense of duty I am deeply honored to serve our community for another three years.

I am sending you a fact-sheet (in English, Portuguese, Spanish and French) that recalls some of my working methods for your kind information. I hope this fact-sheet can facilitate our joint work. Kindly distribute it among your network.


This mandate is a people-centred mandate and its work and success reflects our collective struggle as a community.

I am looking forward to these three years ahead with great expectations that together we can make a positive difference!


With warm regards,


Alice


 

PORTUGUÊS


Carxs amigxs e parceirxs,


Ao começar o meu segundo termo como Relatora Especial, gostaria de agradecer a todxs e a cada um/a de vocês pelo precioso apoio dado ao meu mandato durante seu primeiro termo. Com um peso adicional de responsabilidade e sentido de dever, estou profundamente honrada em servir a nossa comunidade por mais três anos.

Envio-vos um folheto (em inglês, português, espanhol e francês) que relembra alguns dos meus métodos de trabalho para a vossa amável informação. Espero que este folheto possa facilitar nosso trabalho conjunto. Por favor, distribua-o em sua rede.


Este mandato é centrado nas pessoas e seu trabalho e sucesso refletem nossa luta coletiva como comunidade.

Estou ansiosa por estes três anos mais com grandes expectativas de que juntxs possamos fazer uma diferença positiva!


Atenciosamente,


Alice

 

ESPAÑOL


Queridxs amigxs y compañerxs,


Al entrar en mi segundo ciclo como Relatora Especial, quisiera agradecer a todos ya cada uno de ustedes el valioso apoyo brindado a mi mandato durante su primer ciclo. Con un peso adicional de responsabilidad y sentido del deber, me siento profundamente honrada de servir a nuestra comunidad durante otros tres años.

Le envío una hoja informativa (en inglés, portugués, español y francés) que recuerda algunos de mis métodos de trabajo para su amable información. Espero que esta ficha técnica pueda facilitar nuestro trabajo conjunto. Por favor, distribúyalo entre su red.


Este mandato es un mandato centrado en las personas y su trabajo y éxito refleja nuestra lucha colectiva como comunidad.

¡Estoy deseando que lleguen estos tres años con grandes expectativas de que juntos podamos hacer una diferencia positiva!


Con un cordial saludo,


Alice

 

FRANÇAIS


Chers amis et partenaires,


Alors que j'entre dans mon deuxième mandat de Rapporteuse spéciale, je tiens à remercier tous et chacun d'entre vous pour le précieux appui apporté à mon mandat au cours de son premier mandat. Avec un poids supplémentaire de responsabilité et de sens du devoir, je suis profondément honoré de servir notre communauté pendant encore trois ans.


Je vous envoie une fiche (en anglais, portugais, espagnol et français) qui rappelle certaines de mes méthodes de travail pour votre aimable information. J'espère que cette fiche d'information pourra faciliter notre travail commun. Veuillez le distribuer sur votre réseau.


Ce mandat est un mandat centré sur les personnes et son travail et son succès reflètent notre lutte collective en tant que communauté.

J'attends avec impatience ces trois années à venir avec de grandes espérances qu'ensemble, nous pouvons faire une différence positive!


En vous remerciant chaleureusement,


Alice


______________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/c66ea592-8afa-4458-8f5a-ca5ce42f1bdan%40googlegroups.com.